Table 3 Results of univariate and multivariate analysis for disease-free survival
From: Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma
| Variable | Three-year survival rate (%) | Univariate | Multivariate | |
|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | ||
| Age (<70/≥70 years) | 28.9/29.0 | 0.92 | ||
| Sex (M/F) | 30.0/27.7 | 0.80 | ||
| Tumor diameter (<3cm/≥3cm) | 40.1/15.0 | <0.01 | 0.98 (0.55–1.75) | 0.95 |
| Lymph node metastasis (+/−) | 16.1/36.4 | 0.04 | 1.00 (0.56–1.79) | 0.99 |
| Stage (I/II) | 46.8/21.4 | <0.01 | 1.71 (0.88–3.41) | 0.11 |
| Differentiation (well, mod/por) | 31.8/14.8 | <0.01 | 2.71 (1.35–5.16) | <0.01 |
| Lymphatic invasion (+/−) | 23.3/42.5 | 0.04 | 1.14 (0.64–2.07) | 0.65 |
| Venous invasion (+/−) | 25.5/42.7 | 0.06 | ||
| CEA (<5 / ≥5 ng/mL) | 30.0/18.1 | 0.06 | ||
| CA19-9 (<37/≥37 U/mL) | 47.2/19.5 | <0.01 | 2.17 (1.16–4.29) | 0.01 |
| Frailty (+/−) | 13.1/32.6 | 0.02 | 1.48 (0.83–2.55) | 0.18 |
| mGPS (0/1, 2) | 32.9/19.3 | 0.01 | 1.75 (0.94–3.20) | 0.08 |
| PNI (<40/≥40) | 26.1/29.7 | 0.09 | ||
| R0/R1 | 29.1/23.6 | 0.16 |